Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial

Abstract

Psoriasis is associated with poor health-related quality of life, including sleep impairment. Adalimumab treatment improved sleep outcomes and other patient-reported outcomes including health-related quality of life, work productivity, daily activity and disease-related pain.

Keywords

• psoriasis
• therapies
• adalimumab